Christopher Martell - Jun 25, 2025 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Director
Signature
/s/ Charles Schoch, as Attorney-In-Fact for Christopher Martell
Stock symbol
CADL
Transactions as of
Jun 25, 2025
Transactions value $
$520,000
Form type
4
Date filed
6/26/2025, 08:30 AM
Previous filing
Jun 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Martell Christopher Director C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM /s/ Charles Schoch, as Attorney-In-Fact for Christopher Martell 2025-06-26 0001873465

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CADL Common Stock Award $520K +111K $4.67 111K Jun 25, 2025 By Spouse F1, F2
holding CADL Common Stock 152K Jun 25, 2025 By GTAM1 2012 LLC F3
holding CADL Common Stock 284K Jun 25, 2025 By GTAM1 2012 ADV LLC F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired from the Issuer in a registered direct offering pursuant to the terms of a Securities Purchase Agreement dated as of June 23, 2025.
F2 Shares held by Spouse.
F3 Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
F4 Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.